Qiagen Pty Ltd
QIAGEN is the leading provider of sample and assay technologies. Sample technologies are used to isolate DNA, RNA, and proteins from any biological sample. Assay technologies are then used to make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analysis.
|Phone:||03 9840 9800|
|Fax:||03 9840 9888|
Level 1, 90-94 Tram Road , Doncaster VIC 3108 (Directions)
The QIAGEN Clinical Insight (QCI) clinical decision support solution streamlines the annotation, interpretation and reporting of next-generation sequencing results (NGS) for clinical laboratories. The bioinformatics platform has been expanded from interpreting NGS data on somatic mutations in solid tumour cancers to add leukaemia and lymphoma testing, as well as testing for hereditary cancer indications.
Qiagen has entered into a partnership with Eli Lilly and will develop a PCR-based companion diagnostic running on the Rotor-Gene Q instrument that will provide both qualitative and quantitative results for JAK2 V617F.
The Qiagen Multiplex PCR Plus Kit has been designed for rapid and sensitive multiplex PCR that allows researchers to amplify several targets in one PCR run. The kit provides fast reaction times and comes with a preoptimised protocol, eliminating the need for optimisation and delivering reliable results on the first attempt.
The qBiomarker Somatic Mutation PCR Array System has been designed for rapid and accurate mutation profiling in basic research and drug discovery. The assays consist of collections of pathway or cancer-specific assays in 96- or 384-well plate formats with a number of pathways (EGFR, ErbB2, etc) and cancer types.
The Investigator Quantiplex Kit has been designed to quickly confirm that forensic DNA samples contain sufficient DNA for genetic fingerprinting analysis. The kit quantifies the human DNA in the sample and establishes whether it contains inhibitors that may interfere with downstream applications.
Qiagen has launched ScreenGel software for convenient DNA fragment and RNA analysis with the QIAxcel multicapillary gel electrophoresis systems. The software combines the highest possible flexibility for researchers with the ability for standardised and reproducible operations in routine laboratories.
Qiagen has launched several products that assist in the molecular analysis of formalin-fixed, paraffin-embedded (FFPE) tissue samples.
QIAsymphony RGQ is a flexible automated solution for molecular testing. It incorporates all workflow steps from sample to detection.
SABiosciences has released several RT2 Profiler PCR Arrays for gene expression profiling in nephrotoxicity, hepatotoxicology, differentiation and embryonic stem cells markers as well as analysis of epigenetic modulators and enzymes. Covering more than 100 pathways, PCR arrays enable scientists to easily and accurately analyse the gene expression in research areas such as cancer, stem cells, biomarker discovery and immunology.
On the GeneGlobe web portal, users can explore and order gene and pathway specific products for a range of applications. For miRNA research, the miScript target protector is available for researchers doing functional analysis of miRNAs.
The Investigator PCR assays for human identification have been released.
Qiagen has launch its Influenza A/H1N1 test and several updates to its activities in the global surveillance of the swine flu pandemic. The kit enables both the highly sensitive and specific detection of the novel Influenza A/H1N1 and all other known Influenza A and B virus strains. The test kit has been designed for use by governments and public health institutions.
Biomatrica and Qiagen have launched QIAsafe DNA Blood Products, the first dry blood storage available on a matrix based on Biomatrica’s SampleMatrix technology.
Biobanks are the intermediary between donors and research labs to ensure the safe, effective transfer of the biological information held in samples. The number of biobanks is increasing, as is the cost for power to store the samples at the appropriate refrigerated temperature. The current standard for storage is either at -20 or -70 °C. It is costly for biobanks not only to keep these samples cold, but also to house the refrigerators within their laboratories. New methods are being sought to allow storage at room temperature, thus reducing costs as well as being environmentally friendly. Qiagen has launched the QIAsafe DNA Blood Kit to provide easy transport and storage of whole blood at room temperature.
The QIAxcel DNA kits by QIAGEN replaces traditional gel analysis of DNA and RNA. Researchers can perform DNA fragment analysis in as little as ten minutes for 12 samples without the need for agarose gel preparation.
The versatile Rotor-Gene Q real-time PCR cycler features a centrifugal rotary design. Each tube spins in a chamber of moving air, keeping all samples at precisely the same temperature during rapid thermal cycling. Detection is similarly uniform.
The QIAgility is a compact benchtop instrument enabling automated PCR set-up in a wide range of formats.
The centrifugal rotary design of the Rotor-Gene Q makes it a precise, versatile real-time PCR cycler.
PreAnalytiX has received marketing clearance from the US Food and Drug Administration for the automation of the PAXgene Blood RNA System on the QIAcube. This clearance enables laboratories to automate an IVD purification method which is part of an integrated IVD blood collection method for intracellular RNA.
The Rotor-Gene is a rotary real-time PCR cycler system used to detect real-time polymerase chain reaction (PCR) reactions, making specific sequences of DNA and RNA targets visible and quantifiable through amplification.
Qiagen has launched five additions to its EpiTect product line to help address the growing demand for standardised products for complete workflows in epigenetics.
Qiagen has launched a test to determine mutations of the K-ras gene, which can better define which metastatic colorectal cancer (CRC) patients will benefit from treatment with epidermal growth factor receptor (EGFR) inhibiting monoclonal antibodies, such as Amgen’s Vectibix (panitumumab) and Imclone/Bristol-Myers Squibb’s Erbitux (cetuximab).
Analysis of DNA fragments, such as single- or multiplex PCR products and qualitative and quantitative RNA analysis, is easy and fast with the QIAxcel system. It fully automates sensitive, high-resolution capillary electrophoresis of up to 96 samples per run.
Qiagen has added to its portfolio of miRNA technologies with the introduction of the miScript System, which enables detection and quantification of miRNA, as well as mRNA and other small RNA, using SYBR Green-based, real-time PCR.
QuantiFast Kits are claimed to deliver faster results in real-time PCR. With time savings of up to 60% on existing cyclers claimed, there is no need for hardware upgrades. In addition, no PCR optimisation is required, even if using previously established assays. Kits are available for SYBR Green or probe-based detection in PCR, two-step RT-PCR and one-step RT-PCR.
Qiagen has delivered its Human Druggable Genome siRNA Set V2.0 to the Scripps Research Institute in Florida. This second generation siRNA set from Qiagen enables efficient and effective gene silencing studies of 6992 potential human druggable targets. siRNAs are designed using the HiPerformance siRNA Design Algorithm, ensuring maximum silencing and minimum risk of non-specific effects.
Xantos Biomedicine AG and Qiagen have announced their partnership for co-marketing Qiagen's proprietary TOM-amidite chemistry-based genome-wide RNAi products with Xantos' automated cell-based screening platform, XantoScreen. By combining the capabilities of both companies' platforms users will be able to rapidly perform gene analysis and unravel the function and role of genes that are relevant to their area of interest.
BioSprint 15 and BioSprint 96 workstations and kits provide rapid and cost-efficient automated sample preparation - whatever the throughput needs. BioSprint 15 can process 1 to 15 samples or up to 96 samples can be processed with the BioSprint 96.